Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Rocketvax AG currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. Both of these matters are assigned to 1 distinct examiner, creating a high level of consistency in the review process for the company's active applications. This concentration allows for a unified communication strategy with the patent office.
The prosecution is centered in 1 distinct art unit. WANG, RUIXUE is the busiest examiner for the portfolio, overseeing 2 busiest examiner pending actions. These 2 busiest examiner pending actions represent the full scope of the company's current prosecution workload. Because 1 distinct examiner is reviewing different applications within the same 1 distinct art unit, the outcomes are likely to be closely linked. Practitioners should analyze the examiner's prior actions on these 2 pending office actions to identify common themes or objections that may affect the entire biotechnology portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WANG, RUIXUE | 2 | 57.4% | +17.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17909145 | FULLY SYNTHETIC, LONG-CHAIN NUCLEIC ACID FOR VACCINE PRODUCTION TO PROTECT AGAINST CORONAVIRUSES | WANG, RUIXUE | 49d overdue |
| 18280150 | FULLY SYNTHETIC, LONG-CHAIN NUCLEIC ACID FOR VACCINE PRODUCTION TO PROTECT AGAINST CORONAVIRUSES | WANG, RUIXUE | 31d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17909145 | FULLY SYNTHETIC, LONG-CHAIN NUCLEIC ACID FOR VACCINE PRODUCTION TO PROTECT AGAINST CORONAVIRUSES | WANG, RUIXUE | 49d overdue |
| 18280150 | FULLY SYNTHETIC, LONG-CHAIN NUCLEIC ACID FOR VACCINE PRODUCTION TO PROTECT AGAINST CORONAVIRUSES | WANG, RUIXUE | 31d overdue |
| Art Unit | Apps |
|---|---|
| 1672 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18280150 | FULLY SYNTHETIC, LONG-CHAIN NUCLEIC ACID FOR VACCINE PRODUCTION TO PROTECT AGAINST CORONAVIRUSES | WANG, RUIXUE | 1672 | §103§112 | Final Rejection | 31d overdue | Pending | Sep 01, 2023 |
| 17909145 | FULLY SYNTHETIC, LONG-CHAIN NUCLEIC ACID FOR VACCINE PRODUCTION TO PROTECT AGAINST CORONAVIRUSES | WANG, RUIXUE | 1672 | §103§112 | Final Rejection | 49d overdue | Pending | Sep 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial